SEC Tracker
Get the app

Cadrenal Therapeutics CVKD

Cadrenal Therapeutics Q3 FY24: net loss $2.4M; diluted EPS −$2.18

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Cadrenal Therapeutics reported for Q3 FY24, the quarter ended Sep 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$2.4MAgainst −$1.0M in Q3 FY2310-Q income statement, on EDGAR
  2. Diluted EPS−$2.18Against −$0.07 in Q3 FY2310-Q income statement, on EDGAR
  3. Cash and cash equivalents$4.4M−52% from $9.1M in Q3 FY2310-Q balance sheet, on EDGAR
  4. Cash from operations−$2.2MAgainst −$628K in Q3 FY2310-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Cadrenal Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Curis CRIS public float $25M, Jun 30, 2025
  2. Kala Bio KALA public float $25M, Jun 30, 2025
  3. Lexaria Bioscience LEXX public float $25M, Feb 28, 2025, over 18 months old
  4. Pulmatrix PULM public float $25M, Jun 30, 2025
  5. Dyadic International DYAI public float $24M, Jun 30, 2025